These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9354241)

  • 21. Use of 10-formyl-5,8-dideazafolate as substrate for rat 10-formyltetrahydrofolate dehydrogenase.
    Cook RJ
    Methods Enzymol; 1997; 281():129-34. PubMed ID: 9250976
    [No Abstract]   [Full Text] [Related]  

  • 22. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
    Zhang Y; Desharnais J; Marsilje TH; Li C; Hedrick MP; Gooljarsingh LT; Tavassoli A; Benkovic SJ; Olson AJ; Boger DL; Wilson IA
    Biochemistry; 2003 May; 42(20):6043-56. PubMed ID: 12755606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.
    Gossett LS; Habeck LL; Shackelford KA; Mendelsohn LG; Gates SB; Worzalla JF; Self TD; Theobald KS; Andis SL; Schultz RM; Shih C
    Bioorg Med Chem Lett; 1999 Jan; 9(1):75-8. PubMed ID: 9990460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and antifolate properties of 10-alkyl-5,10-dideaza analogues of methotrexate and tetrahydrofolic acid.
    DeGraw JI; Christie PH; Kisliuk RL; Gaumont Y; Sirotnak FM
    J Med Chem; 1990 Feb; 33(2):673-7. PubMed ID: 2299633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
    Wang Y; Mitchell-Ryan S; Raghavan S; George C; Orr S; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2015 Feb; 58(3):1479-93. PubMed ID: 25602637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J; Gaumont Y; Kisliuk RL; Sirotnak FM; Murthy BR; Nair MG; Piper JR
    Cancer Res; 1989 Jan; 49(1):158-63. PubMed ID: 2521177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.
    Varney MD; Palmer CL; Romines WH; Boritzki T; Margosiak SA; Almassy R; Janson CA; Bartlett C; Howland EJ; Ferre R
    J Med Chem; 1997 Aug; 40(16):2502-24. PubMed ID: 9258357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
    White DB; Slocum HK; Brun Y; Wrzosek C; Greco WR
    Curr Drug Metab; 2003 Oct; 4(5):399-409. PubMed ID: 14529372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the cofactor specificity of glycinamide ribonucleotide and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase from chicken liver.
    Smith GK; Mueller WT; Benkovic PA; Benkovic SJ
    Biochemistry; 1981 Mar; 20(5):1241-5. PubMed ID: 7225325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of AICAR Tfase inhibitors that disrupt requisite enzyme dimerization.
    Capps KJ; Humiston J; Dominique R; Hwang I; Boger DL
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2840-4. PubMed ID: 15911265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.
    Itoh F; Russello O; Akimoto H; Beardsley GP
    Cancer Chemother Pharmacol; 1994; 34(4):273-9. PubMed ID: 8033293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint.
    Zhang CC; Boritzki TJ; Jackson RC
    Cancer Chemother Pharmacol; 1998; 41(3):223-8. PubMed ID: 9443639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct transfer of one-carbon units in the transformylations of de novo purine biosynthesis.
    Smith GK; Mueller WT; Slieker LJ; DeBrosse CW; Benkovic SJ
    Biochemistry; 1982 Jun; 21(12):2870-4. PubMed ID: 7104299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
    Bronder JL; Moran RG
    Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
    Lu X; Errington J; Chen VJ; Curtin NJ; Boddy AV; Newell DR
    Clin Cancer Res; 2000 Jan; 6(1):271-7. PubMed ID: 10656458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.